MedPath

the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes

Phase 4
Conditions
Type 2 Diabetes
Interventions
Dietary Supplement: vitamin D
Dietary Supplement: placebo
Registration Number
NCT01876563
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

The aim of this study is the comparision between the effects of vitamin D or placebo supplementation for 2 months in serum level of thioredoxin, TBP-2 and thioredoxin reductase activity in patients with type 2 diabetes

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria

literate, willingness to participation, diabetic patients 30- 60 years old, body mass index in the range 18.5- 35, avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention -

Exclusion Criteria

people who have used vitamin D supplements in last 3 months, having chronic renal disease , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
diabetes, vitamin Dvitamin Dpatients with type 2 diabetes who receive 4000 IU/day vitamin D
placebo, diabetesplacebopatients with type 2 diabetes who receive one tab placebo
Primary Outcome Measures
NameTimeMethod
serum total cholesterolchange from baseline at 2 months
serum HDL cholesterolchange from baseline at 2 months
serum triglycerides levelchange from baseline at 2 months
fasting plasma glucosechange from baseline at 2 months
serum LDL cholesterolchange from baseline at 2 months
complete blood count (CBC)change from baseline at 2 months
HbA1cchange from baseline at 2 months
serum insulinchange from baseline at 2 months
serum calcidiolchange from baseline at 2 months
thioredoxinchange from baseline at 2 months
thioredoxin binding protein 2 (TBP-2)change from baseline at 2 months
erytrocyte thioredoxin reductasechange from baseline at 2 months
Secondary Outcome Measures
NameTimeMethod
GENE EXPRESSION OF TBP-2change from baseline at 2 months

Trial Locations

Locations (1)

Tehran University of Medical Sciences

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath